http://www.ncbi.nlm.nih.gov/pubmed/26756876

Shneider BL, Morris A, Vockley J. Possible Phenylacetate Hepatotoxicity during 4-Phenylbutyrate Therapy of Byler Disease. J Pediatr Gastroenterol Nutr. 2016 Mar; 62(3): 424-8.

Abstract

http://www.ncbi.nlm.nih.gov/pubmed/26485605

Kolachala VL, Jiang R, Abramowsky CR, Gupta NA. Contrast-Based Real-Time Assessment of Microcirculatory Changes in a Fatty Liver after Ischemia Reperfusion Injury. J Pediatric Gastroenterology Nutr. 2016 Mar; 62(3): 429-36.

Abstract

OBJECTIVES:
A fatty liver is known to have impairment of microcirculation, which is worsened after ischemia reperfusion injury (IRI). This makes most fatty grafts unsuitable for transplantation, and in the absence of real time assessment of microcirculation this selection has been at best, random. The aim of this study was to demonstrate the utility of a contrast enhanced ultrasound model in quantitative assessment of the microcirculation of a fatty liver.

METHODS:

http://www.ncbi.nlm.nih.gov/pubmed/26409215

Murillo O, Luqui DM, Gazquez C, Martinez-Espartosa D, Navarro-Blasco I, Monreal JI, Guembe L, Moreno-Cermeño A, Corrales FJ, Prieto J, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G. Long-term metabolic correction of Wilson's disease in a murine model by gene therapy. J Hepatol. 2016 Feb; 64(2):419-26.

Abstract

BACKGROUND & AIMS:
Wilson's disease (WD) is an autosomal recessively inherited copper storage disorder due to mutations in the ATP7B gene that causes hepatic and neurologic symptoms. Current treatments are based on lifelong copper chelating drugs and zinc salts, which may cause side effects and do not restore normal copper metabolism. In this work we assessed the efficacy of gene therapy to treat this condition.

METHODS: